Loncar Cancer Immunotherapy Index Announces Merger Replacement

 

Bicycle Therapeutics Added to the Only Index that Tracks Cancer Immunotherapy

 

Lenexa, KS -- November 17, 2021 -- Loncar Investments, LLC today announced a new addition to the Loncar Cancer Immunotherapy Index, a group of the top 30 companies developing cancer immunotherapy treatments and discovering new ways to use the body’s immune system to fight cancer.

 

The index committee has added Bicycle Therapeutics (Nasdaq: BCYC). It replaces Trillium Therapeutics (Nasdaq: TRIL)

 

The change happens as Trillium Therapeutics is discontinued on the closing of its $2.3 billion acquisition by Pfizer.

    

The above changes were made after a special meeting of the index’s committee and according to its rules. The next regularly scheduled semi-annual rebalance and reconstitution of the index will occur on December 21, 2021. 

 

Loncar Investments is an official partner of the Cancer Research Institute, the world’s longest running nonprofit organization dedicated exclusively to harnessing the immune system’s power to conquer all cancers. To learn about how to give to CRI, please visit here.

 

Why immunotherapy:  Cancer immunotherapy has become an important sector in the biotechnology space and is changing the way many cancers are treated. While traditional medicines like chemotherapies often give cancer a broad punch, the benefit of using immunotherapy is derived from the immune system's dynamic nature and the way it can more precisely be tailored to fight a patient's disease. 

 

About the index:  The Loncar Cancer Immunotherapy Index is an equal-weighted index of 30 top immunotherapy companies rebalanced and reconstituted on a semi-annual basis. Price and return data are independently calculated on a daily basis by Indxx, LLC. Additional information can be found at the index’s dedicated website, www.LoncarIndex.com.

 

Index provider:  Loncar Investments, LLC is committed to making the biotechnology space more approachable to a wider range of investors. The company is principally owned by biotech investor and analyst Brad Loncar. Mr. Loncar manages a biotech-focused family portfolio from his Lenexa, Kan. office. He can be followed on Twitter at @bradloncar and his commentary is available at www.loncarblog.com

 

 

 

Contact:

Jill Tatios, Gregory FCA for Loncar Investments

loncar@gregoryfca.com

215-240-6398

Loncar Investments, LLC : P.O Box 15072, Lenexa, KS  66285 : 913-871-5007 : Not investment advice or a solicitation to buy or sell securities